Sat.Nov 12, 2022 - Fri.Nov 18, 2022

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

In a field dominated by antibodies and small molecules, two cell-therapy based approaches have come under the spotlight for showing early signs of efficacy in treating lupus. In September, a group from Friedrich Alexander University Erlangen-Nuremberg reported that five patients with lupus achieved remission after an infusion of autologous chimeric antigen receptor (CAR)-T cells led to a deep depletion of B cells.

Antibody 362
article thumbnail

Narcan developer to be acquired by Indivior

Bio Pharma Dive

The deal, which could carry a total value of roughly $145 million, is in large part focused on a nasal formulation of the opioid overdose drug nalmefene.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientists Discover X Chromosomes Being ‘Silenced’ in Male Cancer Cells

AuroBlog - Aurous Healthcare Clinical Trials blog

Scientists from the Dana-Farber Cancer Institute have found some male cancer cells, those with X and Y chromosomes, show signs of having their X chromosome silenced. In normal mammal cells, the X chromosome is only muted when a female cell has a pair of Xs to choose from. Randomly turning off an extra X is […].

Scientist 246
article thumbnail

Grand Rounds Ethics and Regulatory Series November 11, 2022: Data Sharing and Pragmatic Clinical Trials: Law & Ethics Amidst a Changing Policy Landscape (Stephanie Morain, PhD, MPH; Kayte Spector-Bagdady, JD, MBioethics)

Rethinking Clinical Trials

? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?. Speakers. Stephanie Morain, PhD, MPH. Assistant Professor. Berman Institute of Bioethics & Johns Hopkins Bloomberg School of Public Health. Kayte Spector-Bagdady, JD, MBioethics. Associate Director, Center for Bioethics & Social Sciences in Medicine. Assistant Professor of Obstetrics & Gynecology.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

NICE to update endometriosis guidelines to improve diagnosis and surgical management

Pharmaceutical Technology

The National Institute of Health and Care Excellence (NICE) has agreed to update its guidelines on endometriosis diagnosis, surgical management, and surgical management when fertility is a priority. The decision came following a surveillance review led by NICE, which identified sufficient new evidence to support this update. This marks the first update to NICE’s endometriosis guidelines since 2017, representing a huge milestone for patients and practitioners alike.

Hormones 257
article thumbnail

Biotechs reveal layoffs, research revamps in third quarter earnings

Bio Pharma Dive

Tricida, Harpoon, Freeline and three other small drug developers have this week announced plans to cut staff or to reprioritize their drug development.

Research 347

More Trending

article thumbnail

Raters & Therapists: Protecting the validity of your study’s data in a psychedelic trial

Worldwide Clinical Trials

Psychiatry has long embraced treatment options other than pharmaceuticals. So, it should come as no surprise that as the field explores the use of psychedelics as treatment options for mental illnesses, they are studying the use of psychological therapy alongside them. This is called “psychedelic-assisted psychotherapy” (PAP). But in a clinical trial setting, what role does a therapist play and how do they affect the clinical trial data?

Trials 147
article thumbnail

US FDA approves Provention Bio’s Tzield to delay diabetes

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Provention Bio’s biologics licence application (BLA) for Tzield (teplizumab-mzwv) to treat type 1 diabetes (T1D) patients. The anti-CD3-directed antibody Tzield aims to delay the onset of Stage 3 T1D in adults and children aged eight years and above who are currently with stage 2 T1D. It is claimed to be the first and only immunomodulatory treatment for T1D and is provided as a sterile, preservative-free, clear, and colourless solution in a

article thumbnail

Freeline cuts back as it continues search for gene therapy partner

Bio Pharma Dive

The U.K. biotech will sell its German unit and lay off staff to save cash as it focuses on therapies for Gaucher and Fabry diseases.

article thumbnail

Brain Zaps Helped These Two Patients Get on Top of Their Binge Eating

AuroBlog - Aurous Healthcare Clinical Trials blog

Electric shocks to the brain took away the cravings of two patients with binge eating disorder for at least six months, a small study said. The two patients were fitted with a brain implant to zap the part of the brain linked to cravings. They told The New York Times that after the surgery they […].

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Carrying out executions took a secret toll on workers — then changed their politics

NPR Health - Shots

NPR spoke with 26 people who were involved with more than 200 executions across the country. Most said their health suffered and they had little support to help them cope with their unusual jobs.

145
145
article thumbnail

ElevateBio and Affini-T collaborate to develop T cell therapies

Pharmaceutical Technology

ElevateBio has entered a partnership with Affini-T Therapeutics to progress the latter’s engineered TCR-T therapies focused on Kirsten rat sarcoma viral oncogene homolog (KRAS), a dominant oncogenic driver mutation in solid tumours. Under the deal, the LentiPeak lentiviral vector technology platform and cell therapy production expertise of ElevateBio BaseCamp will be used by Affini-T to develop its investigational oncogenic driver programmes in the clinic.

article thumbnail

Acrivon cuts IPO price to raise $99M for plan to revive old Lilly cancer drug

Bio Pharma Dive

Acrivon is the 20th biotech company to go public this year, roughly a fifth of last year’s total at this time, and had to sell more shares at a lower price to complete the deal.

Drugs 338
article thumbnail

MSF releases clinical trial transparency policy to promote equity in biomedical R&D ecosystem

AuroBlog - Aurous Healthcare Clinical Trials blog

In a bid to bring transparency in clinical trial costs which will in turn increase equity in the biomedical R&D ecosystem, Médecins Sans Frontières (MSF), a global medical non-governmental organization, has approved and published its first Clinical Trial Transparency Policy (CTTP). This policy is a commitment to publishing research protocols, registering clinical trials on appropriate […].

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Holmes gets more than 11 years in prison for Theranos scam

STAT News

A federal judge on Friday sentenced disgraced Theranos CEO Elizabeth Holmes to more than 11 years in prison for duping investors in the failed startup that promised to revolutionize blood testing but instead made her a symbol of Silicon Valley’s culture of audacious self-promotion. The sentence imposed by U.S. District Judge Edward Davila was shorter than the 15-year penalty requested by federal prosecutors but far tougher than the leniency her legal team sought for the mother of a year-o

145
145
article thumbnail

FDA grants accelerated approval for ImmunoGen’s ovarian cancer ADC

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted accelerated approval for ImmunoGen’s Elahere (mirvetuximab soravtansine-gynx) to treat adults with folate receptor alpha (FR?)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The antibody-drug conjugate (ADC) treatment is indicated for such patients who have previously received one to three systemic therapy regimens, irrespective of the usage of Avastin priorly.

Antibody 246
article thumbnail

First-of-its-kind Type 1 diabetes drug wins FDA approval

Bio Pharma Dive

Provention Bio’s teplizumab is meant to prevent the onset of Type 1 diabetes. To be sold as Tzield, the drug will cost $193,900 for a typical full regimen.

article thumbnail

DoP amends DPCO, 2013 to include NLEM 2022 into Schedule I

AuroBlog - Aurous Healthcare Clinical Trials blog

The Department of Pharmaceuticals (DoP) has issued a notification amending the Drugs (Prices Control) Order, 2013, in order to replace the previous version of National List of Essential Medicines (NLEM) with NLEM, 2022, which was launched in September, this year by the Union health minister Dr Mansukh Mandaviya. The Drugs (Prices Control) Amendment Order, 2022, […].

Medicine 182
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process

STAT News

As the Covid-19 pandemic spread across the world two years ago, one of India’s leading biotech companies was racing to develop a vaccine with crucial backing from the Indian government. The shot engineered by Bharat Biotech was, in part, an important effort to create a home-grown product that could   bolster the fortunes of the Indian pharmaceutical industry.

article thumbnail

Possible cause for Paxlovid rebound uncovered

Pharmaceutical Technology

Two weeks ago, the US Centers for Disease Control and Prevention (CDC) director Rochelle Walensky became the latest high-profile individual to report a case of Paxlovid rebound. Similar cases have been in the news for several months as the antiviral’s use increases, but the cause of such effects has remained mostly unknown. However, a recent study in the Journal of American Medical Association suggests that Paxlovid may not be the sole cause for this relapse in Covid-19 symptoms.

article thumbnail

Eli Lilly’s Julie Gilmore on finding up-and-coming companies and backing small biotechs

Bio Pharma Dive

Only a small fraction of the companies Lilly evaluates get into its incubator, according to Gilmore. Here’s how the big pharma selects them.

328
328
article thumbnail

Health ministry includes coronary stents in NLEM 202

AuroBlog - Aurous Healthcare Clinical Trials blog

The Union ministry of health and family welfare (MoHFW) has notified inclusion of Coronary Stents in the National List of Essential Medicines (NLEM), 2022, with immediate effect based on the recommendations by the expert committee constituted to review and revise the list based on requirement. The Standing National Committee on Medicines (SNCM), on November 6 […].

Medicine 173
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

From science fiction to reality, 'no kill' meat may be coming soon

NPR Health - Shots

The meat of the future may be cultured directly from animal cells without slaughtering livestock. It's not yet sold in the U.S., but NPR got a tour of a leading start-up and a taste of their chicken. (Image credit: Brian L.

145
145
article thumbnail

BioNTech to acquire GMP manufacturing facility in Singapore

Pharmaceutical Technology

BioNTech’s Singapore affiliate BioNTech Pharmaceuticals Asia Pacific has signed an agreement with Novartis Singapore Pharmaceutical Manufacturing to acquire a GMP-certified manufacturing site in the country. . The latest development is part of the expansion plans of BioNTech to boost its international footprint in Asia. . Backed by the Singapore Economic Development Board (EDB), the site will become completely operational late next year.

article thumbnail

After $250M Roche buyout, a startup plans a second strike with fresh funding

Bio Pharma Dive

Backed by the same investors and team as an immunotherapy biotech Roche bought in September, Bonum Therapeutics plans to develop “conditionally” active cancer medicines.

Medicine 322
article thumbnail

Top U.S. addiction researcher calls for broad deregulation of methadone

STAT News

BOSTON — The U.S. government’s top addiction researcher is calling for broad deregulation of methadone , a key drug used to treat opioid use disorder. American doctors should “absolutely” be allowed to prescribe methadone directly to patients, Nora Volkow, the director of the National Institute on Drug Abuse, said Wednesday.

Research 144
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

How banks and hospitals are cashing in when patients can't pay for health care

NPR Health - Shots

Some credit cards advertised by hospitals lure in patients with rosy promises of convenient, low-interest payments on big bills. But interest rates soar if you can't quickly pay off the loan.

143
143
article thumbnail

Indivior agrees to acquire Opiant Pharmaceuticals for $145m

Pharmaceutical Technology

Indivior has signed a definitive agreement to acquire all outstanding shares of Opiant Pharmaceuticals for an upfront payment of $20 for each share in cash or a deal totalling nearly $145m. In addition to the upfront consideration, Opiant is entitled to get up to $8 for a share in contingent value rights (CVRs). . This amount is payable on meeting specific net revenue milestones during the applicable seven-year period following the approval and launch of Opiant’s lead asset, OPNT003.

article thumbnail

Jnana deepens ties with Roche and grabs a new round of funding

Bio Pharma Dive

The company secured $157 million between its second partnership agreement with Roche and a Series C round.

320
320
article thumbnail

New study reveals that exposure to outdoor artificial light at night is associated with an increased risk of diabetes

Medical Xpress

A new study published in Diabetologia finds that outdoor artificial light at night (LAN) is associated with impaired blood glucose control and an increased risk of diabetes, with more than 9 million cases of the disease in Chinese adults being attributed to LAN exposure. The study is by Dr. Yu Xu and colleagues at the Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Medicine 136
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.